{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:53:05Z","timestamp":1790142785937,"version":"4.0.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T00:00:00Z","timestamp":1452124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Angiotensin receptor\u2013neprilysin inhibitors (ARNis) acts an ARB and neprilysin inhibitor. Diabetes mellitus significantly increases the risk of cardiovascular disease and heart failure (HF). Therefore, we evaluated the effects and mechanisms of ARNi in HF with reduced ejection fraction (HFrEF) in streptozotocin-induced diabetic mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Male C57BL\/6J mice were injected with streptozotocin to produce diabetic mice. After myocardial reperfusion injury, diabetic mice were randomized to treatment for 4 weeks with LCZ696 (60\u2009mg\/kg), valsartan (30\u2009mg\/kg), or no treatment (n = 26\u201328 in each group). Cardiac function was assessed by a pressure\u2013volume Millar catheter. The ratios of heart weight to body weight in the valsartan (P = 0.02) and LCZ696 (P = 0.005) groups were significantly less than that in the control group. Treatment with LCZ696 improved LVEF (43\u2009\u00b1\u20093.4%) with a significantly reduction of atrial natriuretic peptide mRNA in the left ventricle compared with that in the control group (29\u2009\u00b1\u20093.2%) (P = 0.006). The fibrotic area in the LCZ696 group was significantly suppressed compared with those in the control (P = 0.003) and valsartan (P = 0.04) groups. Moreover, the mRNA level of transforming growth factor-\u03b2 (TGF-\u03b2) in the left ventricle was suppressed in the LCZ696 group compared with that in the control (P = 0.002) group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The ARNi LCZ696 improved cardiac function with the reduction of fibrosis in an HF-rEF model in diabetic mice, by suppressing TGF-\u03b2. This effect may be due to the specific inhibition of neprilysin, beyond the ARB effect of LCZ696.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.474","type":"journal-article","created":{"date-parts":[[2016,1,10]],"date-time":"2016-01-10T04:29:47Z","timestamp":1452400187000},"page":"386-393","source":"Crossref","is-referenced-by-count":139,"title":["LCZ696, An Angiotensin Receptor\u2013Neprilysin Inhibitor, Improves Cardiac Function with the Attenuation of Fibrosis in Heart Failure with Reduced Ejection Fraction in Streptozotocin-Induced Diabetic Mice"],"prefix":"10.1093","volume":"18","author":[{"given":"Yasunori","family":"Suematsu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]},{"name":"Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshino","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Arimura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kuwano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Yahiro","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Saku","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]},{"name":"Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,1,7]]},"reference":[{"key":"2026011721141491300_ejhf474-bib-0001","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/13543784.2013.797963","article-title":"The potential role of valsartan\u2009+\u2009AHU377 (LCZ696) in the treatment of heart failure","volume":"22","author":"Voors","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"2026011721141491300_ejhf474-bib-0002","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.HYP.0000258532.07418.fa","article-title":"Molecular biology of the natriuretic peptide system: implications for physiology and hypertension","volume":"49","author":"Gardner","year":"2007","journal-title":"Hypertension"},{"key":"2026011721141491300_ejhf474-bib-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2015.06.029","article-title":"Atrial natriuretic peptide in cardiovascular biology and disease (NPPA)","volume":"569","author":"Song","year":"2015","journal-title":"Gene"},{"key":"2026011721141491300_ejhf474-bib-0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2125.1997.00545.x","article-title":"The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides","volume":"43","author":"McDowell","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"2026011721141491300_ejhf474-bib-0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2026011721141491300_ejhf474-bib-0006","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2026011721141491300_ejhf474-bib-0007","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"2026011721141491300_ejhf474-bib-0008","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199911043411901","article-title":"Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction","volume":"341","author":"Zijlstra","year":"1999","journal-title":"N Engl J Med"},{"key":"2026011721141491300_ejhf474-bib-0009","first-page":"396","article-title":"Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras","volume":"4","author":"Cubbon","year":"2011","journal-title":"Circulation"},{"key":"2026011721141491300_ejhf474-bib-0010","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"2026011721141491300_ejhf474-bib-0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011721141491300_ejhf474-bib-0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000214","article-title":"Use of hydralazine\u2013isosorbide dinitrate combination in African American and other race\/ethnic group patients with heart failure and reduced left ventricular ejection fraction","volume":"2","author":"Golwala","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026011721141491300_ejhf474-bib-0013","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ejhf.244","article-title":"MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure","volume":"17","author":"Watson","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026011721141491300_ejhf474-bib-0014","first-page":"299","article-title":"Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotection through a nitric oxide-dependent mechanism","volume":"39","author":"Okawa","year":"2002","journal-title":"J Cardiol"},{"key":"2026011721141491300_ejhf474-bib-0015","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1253\/circj.71.1401","article-title":"Efficacy of continuous low-dose hANP administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome","volume":"71","author":"Sezai","year":"2007","journal-title":"Circ J"},{"key":"2026011721141491300_ejhf474-bib-0016","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.ijcard.2013.03.151","article-title":"Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia\/reperfusion injury","volume":"168","author":"Han","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026011721141491300_ejhf474-bib-0017","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"2026011721141491300_ejhf474-bib-0018","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global burden of diabetes, 1995\u20132025: prevalence, numerical estimates, and projections","volume":"21","author":"King","year":"1998","journal-title":"Diabetes Care"},{"key":"2026011721141491300_ejhf474-bib-0019","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0735-1097(01)01408-5","article-title":"Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction","volume":"38","author":"Dries","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026011721141491300_ejhf474-bib-0020","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0735-1097(03)00856-8","article-title":"The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026011721141491300_ejhf474-bib-0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","article-title":"Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study","volume":"368","author":"Booth","year":"2006","journal-title":"Lancet"},{"key":"2026011721141491300_ejhf474-bib-0022","article-title":"Edaravone protect against retinal damage in streptozotocin-induced diabetic mice","volume":"9","author":"Dongqing","year":"2014","journal-title":"PLoS One"},{"key":"2026011721141491300_ejhf474-bib-0023","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor\u2013neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2026011721141491300_ejhf474-bib-0024","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/nprot.2008.138","article-title":"Measurement of cardiac function using pressure\u2013volume conductance catheter technique in mice and rats","volume":"3","author":"Pacher","year":"2008","journal-title":"Nat Protoc"},{"key":"2026011721141491300_ejhf474-bib-0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"Von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026011721141491300_ejhf474-bib-0026","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejphar.2015.05.059","article-title":"Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage","volume":"762","author":"Bai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"2026011721141491300_ejhf474-bib-0027","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","article-title":"Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging","volume":"125","author":"Giannetta","year":"2012","journal-title":"Circulation"},{"key":"2026011721141491300_ejhf474-bib-0028","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1291\/hypres.26.847","article-title":"Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation","volume":"26","author":"Takahashi","year":"2003","journal-title":"Hypertens Res"},{"key":"2026011721141491300_ejhf474-bib-0029","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/01.RES.0000117070.86556.9F","article-title":"B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-\u03b2 in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation","volume":"94","author":"Kapoun","year":"2004","journal-title":"Circ Res"},{"key":"2026011721141491300_ejhf474-bib-0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/01.CIR.0000138348.77856.ef","article-title":"Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair","volume":"110","author":"Tsuneyoshi","year":"2004","journal-title":"Circulation"},{"key":"2026011721141491300_ejhf474-bib-0031","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1073\/pnas.051625598","article-title":"A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy","volume":"98","author":"Kishimoto","year":"2001","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.474","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/4\/386\/66381171\/eurjhf_18_4_386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/18\/4\/386\/66381171\/eurjhf_18_4_386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:14:37Z","timestamp":1768702477000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/18\/4\/386\/8423365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,7]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,1,7]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.474","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,4]]},"published":{"date-parts":[[2016,1,7]]}}}